AU2017326261A1 - Treatment of multiple sclerosis with CHS-131 - Google Patents
Treatment of multiple sclerosis with CHS-131 Download PDFInfo
- Publication number
- AU2017326261A1 AU2017326261A1 AU2017326261A AU2017326261A AU2017326261A1 AU 2017326261 A1 AU2017326261 A1 AU 2017326261A1 AU 2017326261 A AU2017326261 A AU 2017326261A AU 2017326261 A AU2017326261 A AU 2017326261A AU 2017326261 A1 AU2017326261 A1 AU 2017326261A1
- Authority
- AU
- Australia
- Prior art keywords
- effective amount
- therapeutically effective
- compound
- multiple sclerosis
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HMAAQWIFMFDVCO-UHFFFAOYSA-N Cc(cc(cc1Cl)NS(c(c(Cl)c2)ccc2Cl)(=O)=O)c1Oc1cnc(cccc2)c2c1 Chemical compound Cc(cc(cc1Cl)NS(c(c(Cl)c2)ccc2Cl)(=O)=O)c1Oc1cnc(cccc2)c2c1 HMAAQWIFMFDVCO-UHFFFAOYSA-N 0.000 description 1
- VRWLTCWNFBKTFS-UHFFFAOYSA-N Cc(cc(cc1Cl)NS(c2ccccc2Cl)(=O)=O)c1Oc1cc(cccc2)c2nc1 Chemical compound Cc(cc(cc1Cl)NS(c2ccccc2Cl)(=O)=O)c1Oc1cc(cccc2)c2nc1 VRWLTCWNFBKTFS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394046P | 2016-09-13 | 2016-09-13 | |
| US62/394,046 | 2016-09-13 | ||
| US201662436356P | 2016-12-19 | 2016-12-19 | |
| US62/436,356 | 2016-12-19 | ||
| US201762460868P | 2017-02-19 | 2017-02-19 | |
| US62/460,868 | 2017-02-19 | ||
| US201762491071P | 2017-04-27 | 2017-04-27 | |
| US62/491,071 | 2017-04-27 | ||
| PCT/US2017/051414 WO2018053040A1 (en) | 2016-09-13 | 2017-09-13 | Treatment of multiple sclerosis with chs-131 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017326261A1 true AU2017326261A1 (en) | 2019-04-04 |
Family
ID=61619253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017326261A Abandoned AU2017326261A1 (en) | 2016-09-13 | 2017-09-13 | Treatment of multiple sclerosis with CHS-131 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190224186A1 (https=) |
| EP (1) | EP3512512A4 (https=) |
| JP (1) | JP2019531286A (https=) |
| KR (1) | KR20190064583A (https=) |
| CN (1) | CN110461318A (https=) |
| AU (1) | AU2017326261A1 (https=) |
| BR (1) | BR112019004791A2 (https=) |
| CA (1) | CA3036694A1 (https=) |
| IL (1) | IL265259A (https=) |
| MX (1) | MX2019002901A (https=) |
| SG (1) | SG10202102198RA (https=) |
| WO (1) | WO2018053040A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| EA201992364A1 (ru) * | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
| KR102056756B1 (ko) * | 2013-01-30 | 2019-12-17 | 인테크린 테라퓨틱스, 아이엔씨. | 다발성 경화증의 치료를 위한 PPARγ 작용제 |
-
2017
- 2017-09-13 CN CN201780069826.5A patent/CN110461318A/zh not_active Withdrawn
- 2017-09-13 CA CA3036694A patent/CA3036694A1/en not_active Abandoned
- 2017-09-13 EP EP17851479.0A patent/EP3512512A4/en not_active Withdrawn
- 2017-09-13 US US16/333,171 patent/US20190224186A1/en not_active Abandoned
- 2017-09-13 JP JP2019513922A patent/JP2019531286A/ja active Pending
- 2017-09-13 BR BR112019004791A patent/BR112019004791A2/pt not_active Application Discontinuation
- 2017-09-13 MX MX2019002901A patent/MX2019002901A/es unknown
- 2017-09-13 AU AU2017326261A patent/AU2017326261A1/en not_active Abandoned
- 2017-09-13 WO PCT/US2017/051414 patent/WO2018053040A1/en not_active Ceased
- 2017-09-13 SG SG10202102198RA patent/SG10202102198RA/en unknown
- 2017-09-13 KR KR1020197009963A patent/KR20190064583A/ko not_active Ceased
-
2019
- 2019-03-10 IL IL265259A patent/IL265259A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019531286A (ja) | 2019-10-31 |
| BR112019004791A2 (pt) | 2019-06-04 |
| CA3036694A1 (en) | 2018-03-22 |
| EP3512512A4 (en) | 2020-06-03 |
| WO2018053040A1 (en) | 2018-03-22 |
| CN110461318A (zh) | 2019-11-15 |
| SG10202102198RA (en) | 2021-04-29 |
| IL265259A (en) | 2019-05-30 |
| US20190224186A1 (en) | 2019-07-25 |
| MX2019002901A (es) | 2019-09-26 |
| EP3512512A1 (en) | 2019-07-24 |
| KR20190064583A (ko) | 2019-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chapple et al. | A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | |
| AU2014212740B2 (en) | PPARy agonists for treatment of multiple sclerosis | |
| US20190224186A1 (en) | Treatment of multiple sclerosis with chs-131 | |
| US20200113882A1 (en) | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions | |
| KR20170068480A (ko) | 다발성 경화증의 치료를 위한 시포니모드 및 라퀴니모드를 포함하는 조합물 | |
| US12318380B2 (en) | Treatment of demyelinating diseases | |
| CN119421710A (zh) | 偏头痛的预防治疗 | |
| KR100951540B1 (ko) | 탈수초성 질병 또는 상태 치료용 약제학적 조성물 | |
| EP2882495A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| Nardulli et al. | Combined antimuscarinics for treatment of neurogenic overactive bladder | |
| US20220169508A1 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| KR20250004041A (ko) | 삼차 신경통 치료 및 그와 관련된 통증 감소에 사용하기 위한 트리메프라진 | |
| JP2003535897A (ja) | アンギオテンシンｉｉアンタゴニストの新規使用法 | |
| CN115715191A (zh) | 排尿症状治疗剂 | |
| RU2805061C2 (ru) | Лечение демиелинизирующих заболеваний | |
| Alla et al. | Safety and efficacy of intermittent versus continuous anticholinergic medication in management of overactive bladder in adult | |
| CN121194782A (zh) | 使用布鲁顿酪氨酸激酶抑制剂来治疗复发型多发性硬化症的方法 | |
| KR20230083272A (ko) | 신경병성 통증의 국소 치료에 사용하기 위한 메피라민 | |
| HK1173911B (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |